Randomized Trial: Angiotensin-II Receptor Blockade Reduces the Rate of Aortic Dilatation in Patients with Marfan Syndrome

Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial – The Lancet (free)

Invited Commentary: Angiotensin-II receptor blockade in Marfan syndrome – The Lancet (free)

Related Commentary on Twitter

NEW—Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults with #Marfansyndrome and could reduce the incidence of aortic complications: finding from AIMS, double-blind, placebo-controlled randomised trial https://t.co/uVUWOC062A pic.twitter.com/FPiph5RcJu

— The Lancet (@TheLancet) December 11, 2019